Dose-Escalation Study of HTX-034 Following Bunionectomy
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2, randomized, blinded, active-controlled study. Phase 1b will evaluate
escalating doses of HTX-034 compared with bupivacaine HCl. Phase 2 will be a dose-expansion
phase to evaluate additional subjects treated with the HTX-034 dose selected based on Phase
1b compared with bupivacaine HCl.